NCT02744339View on ClinicalTrials.gov

Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

PHASE2CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

August 31, 2020

Study Completion Date

September 30, 2020

Conditions

Hypertension, PulmonaryHeart Failure With Normal Ejection Fraction

Interventions

DRUG

Riociguat

Adempas up-titrated to max. 1.5mg TID

DRUG

Placebo

Placebo sham-titrated TID

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors

lead

Medical University of Vienna

OTHER

NCT02744339 - Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter